Advances in Psoriasis

1. Front Matter

   Pages i-xviii

   PDF

2. History of Psoriasis

   • John B. Cameron, Abby S. Van Voorhees

   Pages 1-7

3. The Pathophysiology of Psoriasis

   • Jeremy M. Hugh, Marissa D. Newman, Jeffrey M. Weinberg

   Pages 9-19

4. Psoriasis: Clinical Review and Update

   • Ivan Grozdev, Neil J. Korman

   Pages 21-26

5. Psoriasis: Epidemiology, Potential Triggers, Disease Course

   • Ivan Grozdev, Neil J. Korman

   Pages 27-37

6. Psoriatic Arthritis: Clinical Review and Update

   • Shiu-chung Au, Noori Kim, Ari M. Goldminz, Maha Abdulrahman Alkofide, Alice B. Gottlieb

   Pages 39-61

7. Topical Therapy I: Corticosteroids and Vitamin D Analogues

   • Ani L. Tajirian, Leon Kircik

   Pages 63-72

8. Topical Therapy II: Retinoids, Immunomodulators, and Others

   • Lyn C. Guenther

   Pages 73-89

9. Ultraviolet Therapy for Psoriasis

   • Tien V. Nguyen, John Y. M. Koo

   Pages 91-110

10. Laser Therapy for Psoriasis

    • Amylynne J. Frankel, Ellen Henrie Frankel

    Pages 111-115

11. Traditional Systemic Therapy I: Methotrexate and Cyclosporine

    • Robert M. Bacigalupi, Erin Boh

    Pages 117-130

12. Traditional Systemic Therapy II: Retinoids and Others

    • Misha Koshelev, Fareesa Shuja, Ted Rosen

    Pages 131-145

13. Etanercept

    • Andrew F. Alexis, Charlotte M. Clark

    Pages 147-157

14. Adalimumab

    • Elizabeth J. Horn, Jennifer C. Cather

    Pages 159-175

15. Infliximab and Golimumab

    • Cerrene N. Giordano, Robert E. Kalb

    Pages 177-196

16. Ustekinumab

    • Caitriona Ryan, Craig L. Leonardi

    Pages 197-207

17. T-Cell Targeted Therapy: Alefacept and Efalizumab

    • Jerry Bagel

    Pages 209-216

18. Research Pipeline I: Topical Therapies

    • Bassel Mahmoud, Linda Stein Gold

    Pages 217-225

19. Research Pipeline II: Oral Therapeutics

    • Phoebe D. Lu, Joni M. Mazza

    Pages 227-242

20. Research Pipeline III: Biologic Therapies

    • Arielle R. Nagler, Jeffrey M. Weinberg

    Pages 243-251

It has become increasingly clear that psoriatic disease, both of the skin and joints, can be a significant diagnostic and therapeutic challenge for the physician and a debilitating illness for the patient. Genetic and immunologic advances have increased our understanding of the pathophysiology of psoriasis and psoriatic arthritis and there is a need for practically oriented evidence based references to describe the management options open to clinicians. The speed at which developments are occurring in the field also necessitates a novel approach to keeping up with these changes in practice and the need is for a reference that that be updated regularly as the subject requires. Psoriasis is an incredibly fast-moving discipline within dermatology. Guidelines, treatment options and management all change at incredible speed. There is a requirement to provide a comprehensive reference resource to provide practical, user friendly information for the dermatology profession to aid in the decision-making process. Psoriasis is a graphical subdiscipline of medicine and therefore this will have copious illustrations. As a fast moving discipline the emphasis must be on annual updates to ensure that readers are kept up to date on the important areas of development.

• Psoriasis

• St. Luke's -Roosevelt Hospital Center, New York, USA

  Jeffrey M. Weinberg

• Department of Dermatology, Icahn School of Medicine, New York, USA

  Mark Lebwohl

Policies and ethics